KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zimmer Biomet Holdings (ZBH) Accumulated Expenses (2016 - 2025)

Zimmer Biomet Holdings (ZBH) has 16 years of Accumulated Expenses data on record, last reported at $477.1 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 27.84% year-over-year to $477.1 million; the TTM value through Dec 2025 reached $477.1 million, up 27.84%, while the annual FY2025 figure was $477.1 million, 27.84% up from the prior year.
  • Accumulated Expenses reached $477.1 million in Q4 2025 per ZBH's latest filing, up from $373.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $582.3 million in Q4 2022 and bottomed at $184.5 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $363.7 million, with a median of $373.2 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: soared 67.82% in 2021, then dropped 28.37% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $536.2 million in 2021, then rose by 8.6% to $582.3 million in 2022, then decreased by 28.37% to $417.1 million in 2023, then dropped by 10.53% to $373.2 million in 2024, then grew by 27.84% to $477.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $477.1 million in Q4 2025, $373.2 million in Q4 2024, and $417.1 million in Q4 2023.